Skip to main content
OpenTrials
Completed

NCT Number: NCT05403398

BSCU1 and Immune Function

The current study aims to explore a range of possible pathways by which BSCU1 could beneficially modulate the immune system, in three target populations representing the general population.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

3 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

NIZO food research BV

Ede, ZB, 6718, Netherlands

About this study

This exploratory study is designed as a single-arm study with repeated measures, involving three different populations, in which each subject serves as its own control. The duration of the intervention is 4 weeks, with biomarker assessments at baseline, after 2 weeks, and after 4 weeks intervention.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adults

  • 30 ≤ age ≤ 49 years
  • BMI ≥ 18.5 and ≤ 25 kg/m2
  • In good health as assessed during screening (by questionnaire), and the medical investigator's professional judgment
  • Non-smoking

Elderly

  • 65 ≤ age ≤ 79 years
  • BMI ≥ 22.0 and ≤ 28.0 kg/m2
  • Generally healthy as assessed during screening (by questionnaire), and the medical investigator's professional judgment
  • Non-smoking

Children

  • 3 ≤ age ≤ 6 years
  • Healthy BMI, cut-off points will be used as indicated by JGZ
  • Generally healthy as assessed during screening (by parental anamnesis), and the study physician's professional judgment

Exclusion criteria

Adults and elderly

  • Chronic illness (e.g., diabetes mellitus, cardiac insufficiency, respiratory insufficiency, cancer, chronic kidney or liver disease),
  • Acute infection in the past month
  • Gastrointestinal disorders (e.g., inflammatory bowel disease),
  • Acute gastroenteritis in the past 2 months
  • Any vaccination in the past month or any scheduled vaccination during the study period
  • Treatment with antibiotics within 2 months before the start of the study and during the study period
  • Regular use of laxative agents
  • Immunodeficiency disorder
  • Use of anti-inflammatory or immunosuppressive drugs (e.g.cyclosporine, azathioprine, systemic corticosteroids, antibodies)
  • Unexplained weight loss or weight gain of > 3 kg in the 3 months prior to pre-study screening
  • Regular consumption of probiotics within 1 month before start of the study
  • Evidence of current excessive alcohol consumption (>4 consumptions/day or >20 consumptions/week) or drug (ab)use
  • Mental status that is incompatible with the proper conduct of the study

Children

  • Acute respiratory or gastrointestinal infection in the past month
  • Chronic illness (e.g. chronic infections, systemic or metabolic disease)
  • Gastrointestinal disorders (e.g., inflammatory bowel disease),
  • Acute gastroenteritis in the past 2 months
  • Any vaccination in the past month or any scheduled vaccination during the study period
  • Treatment with antibiotics within 2 months before the start of the study and during the study period
  • Immunodeficiency disorder
  • Use of anti-inflammatory or immunosuppressive drugs (e.g.cyclosporine, azathioprine, systemic corticosteroids, antibodies)
  • Regular use of laxative agents
  • Regular consumption of probiotics within 1 month before start of the study

Treatment and study plan

B. subtilis CU1

Dietary Supplement

2 billion CFUs daily, for 4 weeks

Other names: B. subtilis CNCM I-2745

Primary outcomes

  1. Fecal sIgA

    Time frame: 4 weeks

    Change in fecal sIgA concentration

Secondary outcomes

  1. Serum cytokine concentration

    Time frame: 4 weeks

    Change in serum cytokines concentration (e.g. MIP-1α, IL-6, Il-10, IFN-γ, TNF-α, IL-1β) in elderly using a commercial Multiplex Bead Immunoassay (Bio-Rad, Veenendaal, The Netherlands)

  2. Ex-vivo cytokines concentration

    Time frame: 4 weeks

    Change in control and Lipopolysaccharide (LPS) stimulated cytokine (e.g. MIP-1α, IL-6, Il-10, IFN-γ, TNF-α, IL-1β) production in whole blood in adults and elderly using a commercial Multiplex Bead Immunoassay (Bio-Rad, Veenendaal, The Netherlands)

  3. Ex-vivo phagocytosis

    Time frame: 4 weeks

    Ex-vivo phagocytic function of monocytes and granulocytes using the commercial pHrodo, BioParticles phagocytosis assay kit (Invitrogen, ThermoFisher) for flow cytometry

  4. Fecal microbiota

    Time frame: 4 weeks

    Fecal microbiota composition using shotgun metagenomics sequencing

  5. RNA sequencing

    Time frame: 4 weeks

    Gene expression in PBMC (RNA sequencing)

  6. Immune cell phenotyping

    Time frame: 4 weeks

    Immune cell phenotyping will be performed by labelling of the cell with cell specific markers and measured by means of flow cytometry. Two panels of each 8-12 markers will be used for general cell phenotyping, including activation markers, and T cell specific phenotyping in PBMCs.

Sponsors and collaborators

Lead sponsor

Lesaffre International

Industry

Collaborators

  • NIZO Food Research

Registry information

Official study title

Change in Markers of Immune Function Associated With Bacillus Subtilis CU1 Intervention in Different Age Groups

Important dates

Study start
2022
Primary completion
2022
Study completion
2023
First posted
Jun 3, 2022
Registry last updated
Jan 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.